Inventiva (IVA)
NASDAQ:IVA
Want to see IVA full AI Analyst Report?
IVA Stock Chart & Stats
$5.67
-$0.02(-0.90%)
At close: 4:00 PM EST
$5.67
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$2.85 - $7.98
Previous CloseN/A
Volume917.00
Average Volume (3M)99.38K
Market Cap
$1.05B
Enterprise Value$612.74M
Total Cash (Recent Filing)$99.27M
Total Debt (Recent Filing)$59.40M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Sep 23, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding207,707,470
10 Day Avg. Volume175,727
30 Day Avg. Volume99,378
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-25.46
Price to Sales (P/S)164.91
P/FCF Ratio-7.30
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue136.69
Enterprise Value/Gross Profit387.64
Enterprise Value/Ebitda-2.52
Forecast
1Y Price Target
$15.75Price Target Upside177.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$3.95M
Bulls Say, Bears Say
Bulls Say
Mechanism And Market OpportunityLanifibranor's multi‑pathway pan‑PPAR activity addressing inflammation, fibrosis, and insulin resistance, together with a large undiagnosed and untreated patient population, supports meaningful commercial opportunity if efficacy is confirmed.
Phase 3 ReadoutAnalyst highlights that a positive NATiV3 Phase 3 readout confirming prior fibrosis benefits and a consistent safety profile could materially increase the company's valuation.
Trial IntegrityThe late‑stage trial's centralized biopsy reads, randomized dosing, and large, well‑screened enrollment strengthen confidence that observed efficacy signals would be robust and interpretable.
Bears Say
Financial Strain And DilutionRising operating expenses, a large reported net loss, and recent financing dilution have pressured analyst target prices and heighten the risk of additional funding needs if key milestones are delayed.
Safety And Commercial AdoptionReported edema and weight gain associated with the drug could limit physician prescribing and patient uptake, constraining potential market penetration even if efficacy is shown.
Statistical Design RiskA conservatively powered design that anticipates a high placebo response raises the bar for demonstrating benefit and increases the likelihood of an inconclusive Phase 3 outcome.
Inventiva News
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $2.85 and its highest was $7.98 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $1.05B.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Sep 23, 2026 which is in 140 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Mar 30, 2026. The company reported -$1.067 earnings per share for the quarter, missing the consensus estimate of -$0.279 by -$0.788.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.42.
How many shares outstanding does Inventiva have?
Inventiva has 207,707,470 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$1.067 in its last earnings report, missing expectations of -$0.279. Following the earnings report the stock price went up 1.277%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (177.78% Upside)
$15.75 (177.78% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.43%
12-Months-Change
Fundamentals
Return on Equity
1870.38%
Trailing 12-Months
Asset Growth
138.07%
Trailing 12-Months
Company Description
Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
IVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive and execution-focused picture: major operational milestones were achieved (NATiV3 enrollment completion, >1,000 patients, clear Q4 2026 readout target), a solid near-term cash position (EUR 230.9M), conservative powering (>90%) and organizational strengthening for regulatory/commercial readiness. Key risks remain—funding beyond the stated runway depends on tranche/warrant mechanics or future financing, tolerability (weight gain/fluid retention) is a known class risk to be monitored, endpoints have inherent variability, and competition is active. On balance the call emphasized progress, readiness and a clear pathway to a potentially pivotal readout while acknowledging material clinical and financing dependencies.View all IVA earnings summariesIVA Stock 12 Month Forecast
Average Price Target
$15.75
▲(177.78% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―
Ownership Overview
―
Insiders
0.46% Mutual Funds
0.13% Other Institutional Investors
99.30% Public Companies and Individual Investors
Options Prices
Currently, No data available
---